Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS AbbVie Can Achieve 100 Billion Yen Sales Target Ahead of Schedule: President
June 6, 2014
-
REGULATORY MHLW Gets Ball Rolling on OTC Diagnostics Deregulation
June 5, 2014
-
BUSINESS Astellas to Issue Monthly EPPV Reports on Suglat for One Year: Product Manager
June 5, 2014
-
REGULATORY MHLW Should Clear Hurdles, Revise NHI Prices Annually: MOF Budget Examiner
June 4, 2014
-
BUSINESS Teijin Ups FY2015 Japan Sales Target for Feburic to 20-Plus Billion Yen
June 3, 2014
-
REGULATORY Fiscal System Council Renews Call for Annual NHI Price Revision, MHLW Still Guarded
June 2, 2014
-
BUSINESS Daiichi Sankyo to Tout Quick Cardiac Event Reduction for Efient
May 30, 2014
-
REGULATORY Chuikyo to Assess Cost-Effectiveness of 5 Listed Drugs, Industry Leery of Price Cuts
May 29, 2014
-
BUSINESS Novartis to Divest Flu Vaccine Biz within 18 Months
May 28, 2014
-
BUSINESS Taisho Toyama to Center on Safety for Lusefi Promotion: Product Manager
May 27, 2014
-
BUSINESS 3 More SGLT-2 Inhibitors Make Japan Debuts to Trail Suglat
May 26, 2014
-
BUSINESS Blopress AG Rollout Won’t Coincide with June Listing: ASKA Pres.
May 23, 2014
-
BUSINESS Teva Pharma Japan to Postpone NHI Price Listing of All Generics Including Valsartan in June
May 23, 2014
-
ORGANIZATION Dainippon Pres. Tada Elected New Chief of JPMA
May 22, 2014
-
BUSINESS AZ to Highlight Global Data to Push Forxiga: Primary Care Head
May 21, 2014
-
REGULATORY MHLW, MOF, Cabinet Office to Come to Agreement on Once-yearly NHI Price Revision by End May
May 21, 2014
-
BUSINESS Improper Staffer Involvement in 4 More Japan CML Programs: Novartis
May 20, 2014
-
REGULATORY PIC/S Committee OKs Japan’s Accession from July 2014
May 20, 2014
-
ACADEMIA Sapporo Hospital Sorry for Ethical Guidelines Violations in Nesp Clinical Study
May 19, 2014
-
BUSINESS Jury Finds in Favor of Takeda in Actos Lawsuit, Turning Down Plaintiff’s Claim
May 19, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…